Trillium Asset Management LLC Decreases Stake in Novo Nordisk A/S $NVO

Trillium Asset Management LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 11.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 167,334 shares of the company’s stock after selling 21,822 shares during the quarter. Trillium Asset Management LLC’s holdings in Novo Nordisk A/S were worth $8,624,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of NVO. Godfrey Financial Associates Inc. purchased a new stake in Novo Nordisk A/S during the fourth quarter worth $25,000. WealthCollab LLC boosted its position in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares in the last quarter. American National Bank & Trust purchased a new stake in Novo Nordisk A/S during the fourth quarter worth $28,000. Maseco LLP purchased a new stake in Novo Nordisk A/S during the fourth quarter worth $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new stake in Novo Nordisk A/S during the fourth quarter worth $29,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UK regulators approved Novo Nordisk’s daily Wegovy pill, making it the first GLP-1 weight-loss tablet approved in the UK. That expands the company’s obesity franchise beyond injections and could open a new growth channel. UK approves Novo weight-loss pill to edge open European market
• Positive Sentiment: Several follow-up reports highlighted the UK approval as a milestone that could help Novo regain momentum in the obesity market and broaden access to Wegovy through private prescriptions. Novo Nordisk Wegovy pill becomes first daily GLP-1 weight-loss pill approved in the UK
• Positive Sentiment: Analysts also raised FY2026 EPS estimates slightly, signaling still-solid earnings expectations despite recent share-price weakness. Novo Nordisk A/S Trading Down 0.1%
• Neutral Sentiment: Some commentary on the “Wegovy pill” said the approval is encouraging but not yet enough to make certain investors buy, suggesting the market may want more proof of commercial impact before re-rating the stock. Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy
• Negative Sentiment: Novo Nordisk disclosed an IT security incident involving unauthorized access to internal systems and potential data copying, which could pressure investor confidence even though the company said operations were not materially affected. Novo Nordisk hit by cyber incident, probes data breach
• Negative Sentiment: Another report said some U.S. employers may drop GLP-1 obesity-drug coverage in 2027, a potential headwind for long-term demand and reimbursement for Wegovy and rival products. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $43.90 on Friday. The firm has a market capitalization of $196.02 billion, a P/E ratio of 10.31, a P/E/G ratio of 3.93 and a beta of 0.78. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The business’s 50-day simple moving average is $42.28 and its 200-day simple moving average is $46.00.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The business had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Equities analysts predict that Novo Nordisk A/S will post 3.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on NVO shares. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, May 12th. Wolfe Research initiated coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating on the stock. Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd. Finally, Nordea Equity Research downgraded shares of Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.